Targeting kinases in asthma

Expert Opinion on Investigational Drugs

Volumn 14, Issue 10, 2005, Pages 1213-1220

  Blease, Kate ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Asthma; Cellular function; Kinase; Small molecule inhibitors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3,5 DIBROMO 4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIASTHMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GENISTEIN; IMATINIB; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NVP QAB205 AA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN KINASE LCK INHIBITOR; PROTEIN KINASE SYK INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; R 112; R 280; R 406; SPC 105; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; CELL FUNCTION; CLINICAL TRIAL; DRUG DESIGN; DRUG TARGETING; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 27144444110     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.10.1213     Document Type: Review

References (45)

1. BARNES PJ: New drugs for asthma. Nature Reviews (2004) 3:831-844.
2. COHN L, ELIAS JA, CHUPP GL: Asthma: mechianisms of disease persistence and progression. Ann. Rev. Immunol. (2004) 22:789-815
3. DRUKER BJ, LYDON NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. (2000) 105:3-7.
4. BERLIN AA, LUKACS NW: Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am. J. Respir. Crit. Care Med. (2004) 171:35-39.
5. CORTES J, AULT P, KOLLER C et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood (2003) 101:4714-4716.
6. DONG C, DAVIS RJ, FLAVELL RA: MAP kinases in the immune response. Ann. Rev. Immunol. (2002) 20:55-72.
7. JOHNSON GL, LAPADAT R: Mitogen-activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science (2002) 298:1911-1912.
8. ESCOTT KJ, BELVISI MG, BIRRELL MA, WEBBER SE, FOSTER ML, SARGENT CA: Effect of the p38 kinase inhibitor, SB203580, on allergic airway inflammation in the rat. Br. J. Pharmacol. (2000) 131:173-176.
9. UNDERWOOD DC, OSBORN RR, KOTZER CJ et al.: SB239063 a potent p38 MAP kinase inhibitor reduces inflammatory cytokine production, airways eosinophil infiltration and persistence. J. Pharmacol. Exp. Ther. (2000) 293:281-288.
10. KOTLYAROV A, NEININGER A, SCHUBERT C et al.: MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat. Cell Biol. (1999) 1:94-97.
11. DUAN W, CHAN JH, McKAY K et al.: Inhaled p38-α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. (2005) 171:571-578.
12. WESTON CR, DAVIS RJ: The JNK signal transduction pathway. Curr. Opin. Genet. Dev. (2002) 12:14-21.
13. DONG C, YANG DD, WYSK M, WHITMARSH AJ, DAVIS RJ, FLAVELL RA: Defective T cell Differentiation in the absence of JNK1. Science (1998) 282:2092.
14. BENNETT BL, SASAKI DT, MURRAY BW et al.: SP600125 an anthrapyrazolone inhibitor of jun N-terminal kinase. Proc. Natl. Acad. Sci. USA (2001) 98:13681-13686.
15. BENNETT BL: Novel treatments for asthma. Asthma therapy: what's in the pipeline. SMI Conference - asthma: new drug targets and innovative therapeutics, London, UK (2002).
16. 2-terminal kinase in allergic airway inflammation and remodeling: effects of SP600125. Eur. J. Pharmacol. (2005) 506:273-283.
17. SOUSA AR, LANE SJ, SOH C, LEE TH: In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. J. Allergy Clin. Immunol. (1999) 104(3):565-574.
18. DUAN W, CHAN JH, WONG CH, LEUNG BP, WONG WS: Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J. Immunol. (2004) 172:7053-7059.
19. LEE J, JOHNSON P, ROTH M, HUNT N, BLACK: ERK activation and mitogenesis in human airway smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. (2001) 280:L1019-L1029.
20. HUBBARD ST, TILL JH: Protein tyrosine kinase structure and function. Ann. Rev. Biochem. (2000) 69:373-398.
21. LATOUR S, VEILLETTEA: Proximal protein tyrosine kinases in immunorecptor signaling. Curr. Opin. Immuol. (2001) 13:299-306.
22. ADACHI T, ALAM R: The mechanism of IL-5 signal transduction. Am. J. Physiol. (1998) 275:C623-C633.
23. DUAN W, KUO I, SELVARAJAN S, CHUA K, BAY BH, WONG WS: Antiinflammatory effects of Genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am. J. Respir. Crit. Care Med. (2003) 167:185-192.
24. SYANAGI S, INATOME R, TAKANO T, YAMAMURA H: Syk expression and novel function in a wide variety of tissues. Biochem. Biophys. Res. Commun. (2001) 288:495-498.
25. ULANOVA M, PUTTAGUNTA L, MARCET-PALACIOS M et al.: Syk tyrosine kinase participates in β1-integrin signaling and inflammatory responses in airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 288:L497-L507.
26. STENTON GR, ULANOVA M, DERY RE et al.: Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J. Immunol. (2002) 169:1028-1036.
27. HAYLER J, LEGRAND D, BAMMERLIN H et al.: Novel 2,6-disubstituted purines - the synthesis of potent and selective inhibitors of the protein tyrosine kinase syk. Drugs Future (2002) 27:P280.
28. lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line. Mol. Cell. Biol. (1992) 12:4521-4530.
29. lck. Nature (1992) 357:161-164.
30. PERNIS AB, ROTHMAN PB: JAK-STAT signaling in asthma. J. Clin. Invest. (2002) 109:1279-1283.
31. MALAVIYA R, UCKUN FM: Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochem. Biophys. Res. Commun. (1999) 257:807-813.
32. MALAVIYA R, CHEN C, NAVARA C et al.: Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′,5′-dibromo-4′-hydroxyphenyl) amino-6,7-dimethoxyquinazoline (WHI-P97). J. Pharm. Exp. Therap. (2000) 295:912-926.
33. MUELLER C, AUGUST A: Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. J. Immunol. (2003) 170:5056-5063.
34. LIN TA, McINTYRE KW, DAS J et al.: Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry (2004) 43:11056-11062.
35. DRUKER BJ, TAMURA S BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2:561-566.
36. WALKER EH, PERISIC O, STEPHENS L, WILLIAMS RL: Structural insights into phosphoinositide 3-kinase catalysis and signaling. Nature (1999) 402:313-320.
37. CONDLIFFE AM, CADWALLADER KA, WALKER TR, RINTOUL RC, COWBURN AS, CHILVERS ER: Phosphoinositide 3-kinase: a critical signaling event in pulmonary cells. Respir. Res. (2000) 1:24-29.
38. MYOU S, LEFF AR, MYO S et al.: Blockade of inflammation and airway hyper-responsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J. Exp. Med. (2003) 198:1573-1582.
39. DUAN W, AGUINALDO D, LEUNG BP, VLAHOS CJ, WONG WS: An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int. Immunopharmacol. (2005) 5:495-502.
40. POOLE AW, PULA G, HERS I, CROSBY D, JONES ML: PKC-interacting proteins: from function to pharmacology. Trends Pharmacol. Sci. (2004) 25:528-535.
41. BANSAL KS, JHA A, JAISWAL AS, CHHABRA SK: Increased levels of protein kinase C in lymphocytes in asthma: possible mechanism of regulation. Eur. Respir. J. (1997) 10:303-313.
42. H2 cytokines from T lymphocytes by protein kinase C in asthma. J. Tongji Med. Univ. (2001) 21:292-296.
43. KARIN M, YAMAMOTO Y, MAY WANG Q: The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. (2004) 3:17-26.
44. CHIBA Y, MISAWA M: The role of RhoA-mediated Ca(2+) sensitization of bronchial smooth muscle contraction in airway hyperresponsiveness. J. Smooth Muscle Res. (2004) 40:155-167.
45. HENRY PJ, MANN TS, GOLDIE RG: A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. Pulm. Pharmacol. Ther. (2005) 18:67-74.